Targeted proteomics reveals serum amyloid A variants and alarmins S100A8-S100A9 as key plasma biomarkers of rheumatoid arthritis

Nys, Gwenaël; COBRAIVILLE, Gaël; Servais, Anne-Catherine; Malaise, Michel; DE SENY, Dominique; Fillet, Marianne

doi:10.1016/j.talanta.2019.06.044

Article (Scientific journals)

Targeted proteomics reveals serum amyloid A variants and alarmins S100A8-S100A9 as key plasma biomarkers of rheumatoid arthritis

Nys, Gwenaël; COBRAIVILLE, Gaël; Servais, Anne-Catherine et al.

2019 • In Talanta

Peer reviewed

Permalink
https://hdl.handle.net/2268/238336

DOI
10.1016/j.talanta.2019.06.044

PubMed
31357327

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

1-s2.0-S0039914019306691-main.pdf

Publisher postprint (5.59 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] Serum amyloid A (SAA) and S100 (S100A8, S100A9 and S100A12) proteins were previously identified as biomarkers of interest for rheumatoid arthritis (RA). Among SAA family, two closely related isoforms (SAA-1 and SAA-2) are linked to the acute-phase of inflammation. They respectively exist under the form of three (α, β, and γ) and two (α and β) allelic variants. We developed a single run quantitative method for these protein variants and investigated their clinical relevance in the context of RA. The method was developed and validated according to regulations before being applied on plasma coming from RA patients (n = 46), other related inflammatory pathologies (n = 116) and controls (n = 62). Depending on the activity score of RA, SAA1 isoforms (mainly of SAA1α and SAA1β subtypes) were found to be differentially present in plasma revealing their dual role during the development of RA. In addition, the weight of SAA1α in the total SAA response varied from 32 to 80% depending on the pathology studied. A negative correlation between SAA1α and SAA1β was also highlighted for RA early-onset (r = −0.41). SAA2 and S100A8/S100A9 proteins were significantly overexpressed compared to control samples regardless of RA stage. The pathophysiological relevance of these quantitative and qualitative characteristics of the SAA response remains unknown. However, the significant negative correlation observed between SAA1α and SAA1β levels in RA early-onset suggests the existence of still unknown regulatory mechanisms in these diseases.

Disciplines :

Pharmacy, pharmacology & toxicology
Rheumatology

Author, co-author :

Nys, Gwenaël ; Université de Liège - ULiège > Département de pharmacie > Analyse des médicaments

COBRAIVILLE, Gaël ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de rhumatologie

Servais, Anne-Catherine ; Université de Liège - ULiège > Département de pharmacie > Analyse des médicaments

Malaise, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie

DE SENY, Dominique ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de rhumatologie

Fillet, Marianne ; Université de Liège - ULiège > Département de pharmacie > Analyse des médicaments

Language :

English

Title :

Targeted proteomics reveals serum amyloid A variants and alarmins S100A8-S100A9 as key plasma biomarkers of rheumatoid arthritis

Publication date :

01 November 2019

Journal title :

Talanta

Peer reviewed :

Peer reviewed

Available on ORBi :

since 25 July 2019

Statistics

Number of views

106 (10 by ULiège)

Number of downloads

127 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Wells, G., Becker, J., Teng, J., Dougados, M., Schiff, M., Smolen, J., Aletaha, D., Van Riel, P., Validation of the 28-joint Disease Activity Score (DAS28) and European League against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann. Rheum. Dis. 68:6 (2009), 954–960.
De Seny, D., Fillet, M., Meuwis, M.A., Geurts, P., Lutteri, L., Ribbens, C., Bours, V., Wehenkel, L., Piette, J., Malaise, M., Discovery of new rheumatoid arthritis biomarkers using the surface‐enhanced laser desorption/ionization time‐of‐flight mass spectrometry ProteinChip approach. Arthritis Rheum. 52:12 (2005), 3801–3812.
De Seny, D., Fillet, M., Ribbens, C., Marée, R., Meuwis, M.-A., Lutteri, L., Chapelle, J.-P., Wehenkel, L., Louis, E., Merville, M.-P., Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin. Chem. 54:6 (2008), 1066–1075.
De Buck, M., Gouwy, M., Ming Wang, J., Van Snick, J., Opdenakker, G., Struyf, S., Van Damme, J., Structure and expression of different serum amyloid A (SAA) variants and their concentration-dependent functions during host insults. Curr. Med. Chem. 23:17 (2016), 1725–1755.
Paret, C., Schön, Z., Szponar, A., Kovacs, G., Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur. Urol. 57:5 (2010), 859–866.
Kim, Y.J., Gallien, S., El‐Khoury, V., Goswami, P., Sertamo, K., Schlesser, M., Berchem, G., Domon, B., Quantification of SAA1 and SAA2 in lung cancer plasma using the isotype‐specific PRM assays. Proteomics 15:18 (2015), 3116–3125.
de Seny, D., Cobraiville, G., Charlier, E., Neuville, S., Esser, N., Malaise, D., Malaise, O., Calvo, F.Q., Relic, B., Malaise, M.G., Acute-phase serum amyloid a in osteoarthritis: regulatory mechanism and proinflammatory properties. PLoS One, 8(6), 2013, e66769.
Connolly, M., Marrelli, A., Blades, M., McCormick, J., Maderna, P., Godson, C., Mullan, R., FitzGerald, O., Bresnihan, B., Pitzalis, C., Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model. J. Immunol., 2010, ji_0902941.
Cunnane, G., Grehan, S., Geoghegan, S., McCormack, C., Shields, D., Whitehead, A., Bresnihan, B., Fitzgerald, O., Serum amyloid A in the assessment of early inflammatory arthritis. J. Rheumatol. 27:1 (2000), 58–63.
Targońska-Stępniak, B., Majdan, M., Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis. Mediat. Inflamm., 2014, 2014.
Cocco, E., Bellone, S., El-Sahwi, K., Cargnelutti, M., Casagrande, F., Buza, N., Tavassoli, F., Siegel, E., Visintin, I., Ratner, E., Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br. J. Canc., 101(2), 2009, 335.
Urieli-Shoval, S., Finci-Yeheskel, Z., Dishon, S., Galinsky, D., Linke, R.P., Ariel, I., Levin, M., Ben-Shachar, I., Prus, D., Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J. Histochem. Cytochem. 58:11 (2010), 1015–1023.
Wang, J.-Y., Zheng, Y.-Z., Yang, J., Lin, Y.-H., Dai, S.-Q., Zhang, G., Liu, W.-L., Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma. BMC Canc., 12(1), 2012, 365.
Kimura, M., Tomita, Y., Imai, T., Saito, T., Katagiri, A., Ohara‐Mikami, Y., Matsudo, T., Takahashi, K., Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer 92:8 (2001), 2072–2075.
Sung, H.-J., Jeon, S.-A., Ahn, J.-M., Seul, K.-J., Kim, J.Y., Lee, J.Y., Yoo, J.S., Lee, S.-Y., Kim, H., Cho, J.-Y., Large-scale isotype-specific quantification of Serum amyloid A 1/2 by multiple reaction monitoring in crude sera. J. Proteom. 75:7 (2012), 2170–2180.
De Rycke, L., Baeten, D., Foell, D., Kruithof, E., Veys, E.M., Roth, J., De Keyser, F., Differential expression and response to anti‐TNFα treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J. Pathol.: J. Pathol. Soc. Great Britain Ireland 206:1 (2005), 17–27.
Frosch, M., Strey, A., Vogl, T., Wulffraat, N.M., Kuis, W., Sunderkötter, C., Harms, E., Sorg, C., Roth, J., Myeloid‐related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular‐onset juvenile rheumatoid arthritis. Arthritis Rheum.: Off. J. Am. Coll. Rheumatol. 43:3 (2000), 628–637.
Sunahori, K., Yamamura, M., Yamana, J., Takasugi, K., Kawashima, M., Yamamoto, H., Chazin, W.J., Nakatani, Y., Yui, S., Makino, H., The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res. Ther., 8(3), 2006, R69.
Foell, D., Wittkowski, H., Vogl, T., Roth, J., S100 proteins expressed in phagocytes: a novel group of damage‐associated molecular pattern molecules. J. Leukoc. Biol. 81:1 (2007), 28–37.
Stephan, J.R., Nolan, E.M., Calcium-induced tetramerization and zinc chelation shield human calprotectin from degradation by host and bacterial extracellular proteases. Chem. Sci. 7:3 (2016), 1962–1975.
Lügering, N., Stoll, R., Kucharzik, T., Schmid, K.W., Rohlmann, G., Burmeister, G., Sorg, C., Domschke, W., Immunohistochemical distribution and serum levels of the Ca2+-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn's disease. Digestion 56:5 (1995), 406–414.
van Lent, P.L., Grevers, L., Blom, A., Sloetjes, A., Mort, J.S., Vogl, T., Nacken, W., Van Den Berg, W., Roth, J., Myeloid related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann. Rheum. Dis., 2007.
Chen, Y.-S., Yan, W., Geczy, C.L., Brown, M.A., Thomas, R., Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res. Ther., 11(2), 2009, R39.
Vogl, T., Pröpper, C., Hartmann, M., Strey, A., Strupat, K., van den Bos, C., Sorg, C., Roth, J., S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J. Biol. Chem. 274:36 (1999), 25291–25296.
Kuzyk, M.A., Hardie, D.B., Yang, J., Smith, D.S., Jackson, A.M., Parker, C.E., Borchers, C.H., A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin. J. Proteome Res. 9:10 (2010), 5422–5437.
Nacken, W., Kerkhoff, C., The hetero‐oligomeric complex of the S100A8/S100A9 protein is extremely protease resistant. FEBS Lett. 581:26 (2007), 5127–5130.
Riva, M., He, Z., Källberg, E., Ivars, F., Leanderson, T., Human S100A9 protein is stabilized by inflammatory stimuli via the formation of proteolytically-resistant homodimers. PLoS One, 8(4), 2013, e61832.
Nordal, H.H., Fagerhol, M.K., Halse, A.-K., Hammer, H.B., Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis. Scand. J. Clin. Lab. Invest. 78:1–2 (2018), 102–108.
Gaitonde, S., Samols, D., Kushner, I., C‐reactive protein and systemic lupus erythematosus. Arthritis Care Res. 59:12 (2008), 1814–1820.
Baillet, A., Trocmé, C., Berthier, S., Arlotto, M., Grange, L., Chenau, J., Quétant, S., Sève, M., Berger, F., Juvin, R., Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology 49:4 (2010), 671–682.
Deane, K.D., O'Donnell, C.I., Hueber, W., Majka, D.S., Lazar, A.A., Derber, L.A., Gilliland, W.R., Edison, J.D., Norris, J.M., Robinson, W.H., The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age‐dependent manner. Arthritis Rheum. 62:11 (2010), 3161–3172.
Liao, H., Wu, J., Kuhn, E., Chin, W., Chang, B., Jones, M.D., O'neil, S., Clauser, K.R., Karl, J., Hasler, F., Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum. 50:12 (2004), 3792–3803.